These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20585055)

  • 41. What is the best size descriptor to use for pharmacokinetic studies in the obese?
    Green B; Duffull SB
    Br J Clin Pharmacol; 2004 Aug; 58(2):119-33. PubMed ID: 15255794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glucocorticoids dosing in obese subjects: A systematic review.
    Delaleu J; Destere A; Hachon L; Declèves X; Lloret-Linares C
    Therapie; 2019 Sep; 74(4):451-458. PubMed ID: 30928086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ontogeny of Drug-Metabolizing Enzymes.
    Thakur A; Parvez MM; Leeder JS; Prasad B
    Methods Mol Biol; 2021; 2342():551-593. PubMed ID: 34272706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gaps in Drug Dosing for Obese Children: A Systematic Review of Commonly Prescribed Emergency Care Medications.
    Rowe S; Siegel D; Benjamin DK;
    Clin Ther; 2015 Sep; 37(9):1924-32. PubMed ID: 26323523
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of Antimicrobials in Obese Children.
    Sampson M; Cohen-Wolkowiez M; Benjamin D; Capparelli E; Watt K
    GaBI J; 2013; 2(2):76-81. PubMed ID: 25009734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD.
    Morse JD; Cortinez LI; Anderson BJ
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling.
    Gerhart JG; Carreño FO; Edginton AN; Sinha J; Perrin EM; Kumar KR; Rikhi A; Hornik CP; Harris V; Ganguly S; Cohen-Wolkowiez M; Gonzalez D;
    Clin Pharmacokinet; 2022 Feb; 61(2):307-320. PubMed ID: 34617262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and Pharmacodynamics of Drugs in Obese Pediatric Patients: How to Map Uncharted Clinical Territories.
    Krekels EHJ; Knibbe CAJ
    Handb Exp Pharmacol; 2020; 261():231-255. PubMed ID: 31598838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes.
    Zhang T; Krekels EHJ; Smit C; Knibbe CAJ
    Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):657-674. PubMed ID: 36217846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens.
    Roberts DM; Sevastos J; Carland JE; Stocker SL; Lea-Henry TN
    Clin J Am Soc Nephrol; 2018 Aug; 13(8):1254-1263. PubMed ID: 30042221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterizing Pharmacokinetics in Children With Obesity-Physiological, Drug, Patient, and Methodological Considerations.
    Gerhart JG; Balevic S; Sinha J; Perrin EM; Wang J; Edginton AN; Gonzalez D
    Front Pharmacol; 2022; 13():818726. PubMed ID: 35359853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and drug dosing in obese children.
    Kendrick JG; Carr RR; Ensom MH
    J Pediatr Pharmacol Ther; 2010 Apr; 15(2):94-109. PubMed ID: 22477800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.
    Lucas CJ; Martin JH
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S78-S98. PubMed ID: 28921641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug dosing in the elderly patients with chronic kidney disease.
    Olyaei AJ; Bennett WM
    Clin Geriatr Med; 2009 Aug; 25(3):459-527. PubMed ID: 19765493
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children.
    Kyler KE; Wagner J; Hosey-Cojocari C; Watt K; Shakhnovich V
    Paediatr Drugs; 2019 Oct; 21(5):357-369. PubMed ID: 31432433
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Drug dosage in obese children].
    Gade C; Christensen HR; Holst H
    Ugeskr Laeger; 2015 Oct; 177(44):V05150446. PubMed ID: 26509544
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Effects of Obesity on Drug Metabolism in Children.
    Oeser SG; Rougee LR; Collier AC
    Drug Metab Lett; 2015; 9(2):88-98. PubMed ID: 26411468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An aid to drug dosing safety in obese children: development of a new nomogram and comparison with existing methods for estimation of ideal body weight and lean body mass.
    Callaghan LC; Walker JD
    Anaesthesia; 2015 Feb; 70(2):176-82. PubMed ID: 25289986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic alterations in obesity.
    Lee JB; Winstead PS; Cook AM
    Orthopedics; 2006 Nov; 29(11):984-8. PubMed ID: 17134048
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Considerations for dosing immunoglobulin in obese patients.
    Hodkinson JP
    Clin Exp Immunol; 2017 Jun; 188(3):353-362. PubMed ID: 28263379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.